Atlas Trials

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

Clinical trial NCT02311673 · COMPLETED

Trial details

NCT number
NCT02311673
Sponsor
Rhythm Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Prader-Willi Syndrome
Start date
2015-03-19
Primary completion
2016-10-26
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.